An index of barriers for the implementation of personalised medicine and pharmacogenomics in Europe

Public Health Genomics

Volumn 17, Issue , 2014, Pages 287-298

  Horgan, Denis ^a   Jansen, Marleen ^b   Leyens, Lada ^b   Lal, Jonathan A ^b   Sudbrak, Ralf ^d   Hackenitz, Erica ^c   Bußhoff, Ulrike ^e   Ballensiefen, Wolfgang ^e   Brand, Angela ^b  

^a European Alliance for Personalised Medicine   (Belgium)

^b MAASTRICHT UNIVERSITY   (Netherlands)

^c ZonMw The Netherlands Organisation for Health Research and Development   (Netherlands)

^d MAX PLANCK INSTITUTE FOR MOLECULAR GENETICS   (Germany)

^e GERMAN AEROSPACE CENTER DLR   (Germany)

Author keywords

Europe; European Alliance for Personalised Medicine; Implementation; Index of barriers; Literature review; PerMed project; Personalised medicine; Pharmacogenomics; Stakeholders; Translation

Indexed keywords

ARTICLE; EUROPE; FUNDING; HEALTH CARE MANAGEMENT; HEALTH CARE PLANNING; HEALTH CARE POLICY; HEALTH CARE SYSTEM; HEALTH CARE UTILIZATION; HUMAN; INFORMED CONSENT; INTERVIEW; MEDICAL RESEARCH; PERSONALIZED MEDICINE; PHARMACOGENOMICS; RISK FACTOR; STANDARDIZATION; STRATEGIC PLANNING; SYSTEMATIC REVIEW; ATTITUDE TO HEALTH; FEMALE; GENETIC MARKER; GENETICS; HEALTH CARE DELIVERY; INFORMATION PROCESSING; MANAGEMENT; PHARMACOGENETICS; POLICY; PSYCHOLOGY; PUBLIC HEALTH SERVICE;

GENETIC MARKER;

ATTITUDE TO HEALTH; DATA COLLECTION; DELIVERY OF HEALTH CARE; EUROPE; FEMALE; GENETIC MARKERS; HUMANS; INDIVIDUALIZED MEDICINE; PHARMACOGENETICS; POLICY MAKING; PUBLIC HEALTH PRACTICE; PUBLIC POLICY;

EID: 84911493416     PISSN: 16624246     EISSN: 16628063     Source Type: Journal    
DOI: 10.1159/000368034     Document Type: Article

References (79)

1. Abrahams E, Silver M: The case for personalized medicine. J Diabetes Sci Technol 2009; 3: 680-684.
2. Chan IS, Ginsburg GS: Personalized medicine: progress and promise. Annu Rev Genomics Hum Genet 2011; 12: 217-244.
3. iNNOVAHEALTH: Building on open innovation ecosystem in Europe for healthcare. Cyprus EU Presidency. iNNOVAHEALTH Conference, Larnaca, October 2012.
4. Pirmohamed M: Acceptance of biomarkerbased tests for application in clinical practice: criteria and obstacles. Clin Pharmacol Ther 2010; 88: 862-866.
5. Squassina A, Manchia M, Manolopoulos VG, Artac M, Lappa-Manakou C, Karkabouna S, Mitropoulos K, Del Zompo M, Patrinos GP: Realities and expectations of pharmacogenomics and personalized medicine: impact of translating genetic knowledge into clinical practice. Pharmacogenomics 2010; 11: 1149-1167.
6. Davis JC, Furstenthal L, Desai AA, Norris T, Sutaria S, Fleming E, Ma P: The microeconomics of personalized medicine: today's challenge and tomorrow's promise. Nat Rev Drug Discov 2009; 8: 279-286.
7. Cohen JP: Overcoming regulatory and economic challenges facing pharmacogenomics. N Biotechnol 2012; 29: 751-756.
8. European Alliance for Personalised Medicine. http://euapm.eu/who-we-are/ (accessed March 5, 2014).
9. Burt T, Dhilloon S: Pharmacogenomics in early-phase clinical development. Pharmacogenomics 2013; 14: 1085-1097.
10. Johnson JA, Cavallari LH: Pharmacogenetics and cardiovascular disease - implications for personalized medicine. Pharmacol Rev 2013; 65: 987-1009.
11. Bakhouche H, Slanař O: Pharmacogenetics in clinical practice. Prague Med Rep 2012; 113: 251-261.
12. Scott SA: Personalizing medicine with clinical pharmacogenetics. Genet Med 2011; 13: 987-995.
13. Gervasini G, Benítez J, Carrillo JA: Pharmacogenetic testing and therapeutic drug monitoring are complementary tools for optimal individualization of drug therapy. Eur J Clin Pharmacol 2010; 66: 755-774.
14. Sorich MJ, McKinnon RA: Personalized medicine: potential, barriers and contemporary issues. Curr Drug Metab 2012; 13: 1000-1006.
15. Staratschek-Jox A, Schultze JL: Re-overcoming barriers in translating biomarkers to clinical practice. Expert Opin Med Diagn 2010; 4: 103-112.
16. Johnson DR, Galanis E: Incorporation of prognostic and predictive factors into glioma clinical trials. Curr Oncol Rep 2013; 15: 56-63.
17. Deverka PA: Pharmacogenomics, evidence, and the role of payers. Public Health Genomics 2009; 12: 149-157.
18. Mousses S, Kiefer J, Von Hoff D, Trent J: Using biointelligence to search the cancer genome: an epistemological perspective on knowledge recovery strategies to enable precision medical genomics. Oncogene 2008; 27(suppl 2):S58-S66.
19. Fiore L, D'Avolio LW: Detours on the road to personalized medicine: barriers to biomarker validation and implementation. JAMA 2011; 306: 1914-1915.
20. West M, Ginsburg GS, Huang AT, Nevins JR: Embracing the complexity of genomic data for personalized medicine. Genome Res 2006; 16: 559-566.
21. Khoury MJ, Gwinn M, Ioannidis JPA: The emergence of translational epidemiology: from scientific discovery to population health impact. Am J Epidemiol 2010; 172: 517-524.
22. Roden DM: Cardiovascular pharmacogenomics: the future of cardiovascular therapeutics? Can J Cardiol 2013; 29: 58-66.
23. Personalized Medicine: PerMed - FP 7 Project. Sponsored by the European Commission. 2014.
24. Personalized Medicine (PerMed): http:// www.permed2020.eu/1401.php (accessed March 5, 2014).
25. Chung WK: Implementation of genetics to personalize medicine. Gend Med 2007; 4: 248-265.
26. Ely S: Personalized medicine: individualized care of cancer patients. Transl Res 2009; 154: 303-308.
27. US Food and Drug Administration: Paving the way for Personalised Medicine: FDA's Role in a New Era of Medical Product Development. 2013. http://www.fda.gov/downloads/ scienceresearch/specialtopics/personalizedmedicine/ ucm372421.pdf.
28. Perez EA: Breast cancer management: opportunities and barriers to an individualized approach. Oncologists 2011; 16(suppl 1):20-22.
29. Roden DM: Cardiovascular pharmacogenomics: the future of cardiovascular therapeutics? Can J Cardiol 2013; 29: 58-66.
30. Cohen MJ, Ginsburg GS, Abrahams E, Bitterman H, Karnieli E: Overcoming barriers in the implementation of personalized medicine into clinical practice. Isr Med Assoc J 2013; 15: 599-601.
31. Deverka PA, Vernon J, McLeod HL: Economic opportunities and challenges for pharmacogenomics. Annu Rev Phamacol Toxicol 2010; 50: 423-437.
32. L'Office parlementaire d'évaluation des choix scientifiques et technologiques: Rapport provisoire: les progrès de la génétique, vers une médecine de précision? Les enjeux scientifiques, technologiques, sociaux et éthiques de la médecine personnalisée. 2014.
33. Nunn AD: Molecular imaging and personalized medicine: an uncertain future. Cancer Biother Radiopharm 2007; 22: 722-739.
34. PricewaterhouseCoopers (PwC), European Hospital and Healthcare Federation (HOPE): Personalized Medicine in European Hospitals. 2011.
35. Babić N: Clinical pharmacogenomics and concept of personalized medicine. J Med Biochem 2012; 31: 281-286.
36. Ieiri I: What are barriers to pharmacogenomics (PGx) clinical uptake? Drug Metab Pharmacokinet 2012; 27: 279.
37. Love D, Stratton E, Stocum M: Best practices for companion diagnostic and therapeutic development: translating between the stakeholders. N Biotechnol 2012; 29: 689-694.
38. Overby CL, Tarczy-Hornoch P: Personalized medicine: challenges and opportunities for translational bioinformatics. Pers Med 2013; 10: 453-462.
39. Weitzel JN, Blazer KR, MacDonald DJ, Culver JO, Offit K: Genetics, genomics and cancer risk assessment: state of the art and future directions in the era of personalized medicine. CA Cancer J Clin 2011; 61: 327-359.
40. Zineh I, Lesko LJ: Pharmacogenetics in medicine: barriers, critical factors and a framework for dialogue. Pers Med 2009; 6: 359-361.
41. Ginsburg GS: Barriers and Solutions to Implementing Personalized Medicine (presentation). Duke University, Durham, North Carolina, 2012.
42. O'Donnell PH, Bush A, Spitz J, Danahey K, Saner D, Das S, Cox NJ, Ratain MJ: The 1200 patients project: creating a new medical model system for clinical implementation of pharmacogenomics. Clin Pharmacol Ther 2012; 92: 446-449.
43. Patel JN: Application of genotype-guided cancer therapy in solid tumors. Pharmacogenomics 2014; 15: 79-93.
44. Williams MS: The public health genomics translation gap: what we don't have and why it matters. Public Health Genomics 2012; 15: 132-138.
45. European Alliance for Personalised Medicine: Innovation and patient access to personalized medicine. Report Irish Presidency Conference, Dublin, March 2013.
46. Ackerman MJ, Filart R, Burgess LP, Lee I, Poropatich RK: Developing next-generation telehealth tools and technologies: patients, systems, and data perspectives. Telemed J E Health 2010; 16: 93-95.
47. Coleman H, Ashcraft K: Genelex Corporation. Pharmacogenomics 2008; 9: 469-475.
48. Pulley JM, Denny JC, Peterson JF, Bernard GR, Vnencak-Jones CL, Ramirez AH, Delaney JT, Bowton E, Brothers K, Johnson K, Crawford DC, Schouldcrout J, Masys DR, Dilks HH, Wilke RA, Calyton EW, Shultz E, Laposata M, McPherson J, Jirjis JN, Roden DM: Operational implementation of prospective genotyping for personalized medicine: the design of the Vanderbilt PREDICT Project. Clin Pharmacol Ther 2012; 92: 87-95.
49. Reynolds KS: Achieving the promise of personalized medicine. Clin Pharmacol Ther 2012; 92: 401-405.
50. Bonter K, Desjardins C, Currier N, Pun J, Ashbury F: Personalised medicine in Canada: a survey of adoption and practice in oncology, cardiology and family medicine. BMJ Open 2011; 1:e000110.
51. Pellegrini I, Rapti M, Extra JM, Petri-Cal A, Apostolidis T, Ferrero JM, Bachelot T, Viens P, Bertucci F, Julian-Reynier C: Targeted chemotherapy for breast cancer: patients perception of the use of tumor gene profiling approaches to better adapt treatments (in French). Med Sci (Paris) 2012; 28(Spec No 1):24-27.
52. European Alliance for Personalised Medicine: EAPM: Big Data workshop. 16th European Health forum. Gastein, October 2013.
53. Moridani M, Maitland-van der Zee AH, Sasaki H, McKinnon R, Fleckenstein L, Shah VP: AAPS-FIP summary workshop report: Pharmacogenetics in individualized medicine: methods, regulatory, and clinical applications. AAPS J 2009; 11: 214-216.
54. Crews KR, Cross SJ, McCormick JN, Baker DK, Molinelli AR, Mullins R, Relling MV, Hoffman JM: Development and implementation of a pharmacist-managed clinical pharmacogenetics service. Am J Health Syst Pharm 2011; 68: 143-150.
55. Aspinall MG, Hamermesh RG: Realizing the promise of personalized medicine. Harv Bus Rev 2007; 85: 108-117.
56. Büro für Technikfolgen-Abschätzung beim Deutschen Bundestag: Individualisierte Medizin und Gesundheitssystem. Zukunftsreport. 2008. http://www.bfa-gemeinschaft.de/ index.php/grundsaetze-u-ziele/68-bundestag/ soziale-sicherheit/164-zukunftsmedizin- forschung-im-berich-individualisiertemedizin.
57. McKinnon R, Ward MB, Sorich MJ: A critical analysis of barriers to the clinical implementation of pharmacogenomics. Ther Clin Risk Manag 2007; 3: 751-759.
58. Crews KR, Hicks JK, Pui CH, Relling MV, Evans WE: Pharmacogenomics and individualized medicine: translating science into practice. Clin Pharmacol Ther 2012; 92: 467-475.
59. Chadwell K: Clinical practice on the horizon: personalized medicine. Clin Nurse Spec 2013; 27: 36-43.
60. European Science Foundation: Personalized medicine for the European citizen. Towards more precise medicine for the diagnosis, treatment and prevention of disease (iPM). 2012. http://www.esf.org/uploads/media/ Personalised-Medicine.pdf.
61. Haddy CA, Ward HM, Angley MT, McKinnon RA: Consumers' views of pharmacogenetics - a qualitative study. Res Social Adm Pharm 2010; 6: 221-231.
62. Cornetta K, Brown CG: Balancing personalized medicine and personalized care. Acad Med 2013; 88: 309-313.
63. Shastry BS: Pharmacogenetics and the concept of individualized medicine. Pharmacogenomics J 2006; 6: 16-21.
64. Butrick M, Roter D, Kaphingst K, Erby LH, Haywood C Jr, Beach MC, Levy HP: Patient reactions to personalized medicine vignettes: an experimental design. Genet Med 2011; 13: 421-428.
65. Luque JS, Quinn GP, Montel-Ishino FA, Arevalo M, Bynum SA, Noel-Thomas S, Wells KJ, Gwede CK, Meade CD; Tampa Bay Community Cancer Network Partners: Formative research on perceptions of biobanking: what community members think. J Cancer Educ 2012; 27: 91-99.
66. Ronquillo JG: How the electronic health record will change the future of health care. Yale J Biol Med 2012; 85: 379-386.
67. Hood L, Friend SH: Predictive, personalized, preventive, participatory (P4) cancer medicine. Nat Rev Clin Oncol 2011; 8: 184-187.
68. Harvey A, Brand A, Holgate ST, Kristiansen LV, Lehrach H, Palotie A, Prainsack B: The future of technologies for personalised medicine. N Biotechnol 2012; 29: 625-633.
69. Mesko B, Zahuczky G, Nagy L: The triad of success in personalised medicine: pharmacogenomics, biotechnology and regulatory issues from a Central European perspective. N Biotechnol 2012; 29: 741-750.
70. Weldon CB, Trosman JR, Gradishar WJ, Benson AB 3rd, Schink JC: Barriers to the use of personalized medicine in breast cancer. J Oncol Pract 2012; 8:e24-e31.
71. Enchin H: Clinician adoption of genetic testing for drug metabolizing enzymes: is patient safety the low-hanging fruit of personalized medicine? AMIA Annu Symp Proc 2009; 2009: 168-172.
72. Brand A, Lal JA; Public Health Genomics European Network: European Best Practice Guidelines for Quality Assurance, Provision and use of Genome-based Information Technologies: the 2012 Declaration of Rome. Drug Metab Drug Interact 2012; 27: 177-182.
73. Gaisser S, Vignola-Gagné E, Hüsing B, Enzing C, van der Valk T: EU policies in personalized medicine-related technologies. Pers Med 2009; 6: 93-102.
74. Lejeune S, Lacombe D: Towards personalized medicine in the EU: what is needed to facilitate the complex international clinical research? Pers Med 2013; 10: 849-857.
75. Pignatti F, Ehmann F, Hemmings R, Jonsson B, Nueblin M, Papaluca-Amati M, Posch M, Rasi G: Cancer drug development and the evolving regulatory framework for companion diagnostics in the European union. Clin Cancer Res 2014; 20: 1458-1468.
76. Miller I, Ashton-Chess J, Spolders H, Fert V, Ferrara J, Kroll W, Askaa J, Larcier P, Terry PF, Bruinvels A, Huriez A: Market access challenges in the EU for high medical value diagnostic tests. Pers Med 2011; 8: 137-148.
77. eHealthTaskForce: Redesign Health in Europe for 2020. European Union 2012.
78. Regniault A, Kupecz A, Gavey M, Mignolet O, De Carlo P, Meyer P, Bailey S: Legal and ethical concerns in personalized medicine: a European perspective. Pers Med 2009; 6: 517-528.
79. Payne K, Annemans L: Reflections on market access for personalized medicine: recommendations for Europe. Value Health 2013; 16(suppl 6):S32-S38.